Matthew W. Vanbrocklin
Professor
Department of Oncological Sciences
Huntsman Cancer Institute
United States of America
Biography
Matthew VanBrocklin, PhD, is an assistant professor in the Department of Surgery at the University of Utah Hospital, an investigator at the Huntsman Cancer Institute (HCI), and a member of the Cell Response and Regulation program.At HCI, VanBrocklin researches novel therapeutic targets and signal transduction pathways (networks inside a cell that transmit outside signals to influence cellular responses) that are important for increasing survival in melanoma, non-small cell lung cancer (NSCLC), and brain tumors. He also aims to develop novel small peptide-based agents directed at therapeutic targets that are currently considered "undruggable".Before joining HCI, VanBrocklin was a researcher at the Nevada Cancer Institute, where he completed a postdoctoral fellowship, established his own lab, and became a member of the Drug Development Division. He received a PhD in biomedical science from Western Michigan University in Kalamazoo, Michigan.
Research Interest
Molecular Targets Melanoma Carcinoma, Non-Small-Cell Lung
Publications
-
Cohen AL, Ray A, Van Brocklin MW, Burnett DM, Bowen RC, Dyess DL, Butler TW, Dumlao T, Khong HT (2016). A Phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. Oncotarget.
-
Shin CH, Robinson JP, Sonnen JA, Welker AE, Yu DX, VanBrocklin MW, Holmen SL (2017). HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss.LID - 10.1038/onc.2017.83 [doi]. (Epub ahead of print) Oncogene.
-
Yang H, Kircher DA, Kim KH, Grossmann AH, VanBrocklin MW, Holmen SL, Robinson JP (2017). Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.LID - 10.1038/onc.2016.526 [doi]. (Epub ahead of print) Oncogene.
